Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

KPRX

Kiora Pharmaceuticals Inc

Nov 17 • 04:00PM ET

2.09

-0.07 -3.24 %

Healthcare • Biotechnology • USA • NASD

Peers: ARWR RGEN EYPT OCUL CLSD ALDX PRQR IRD VSTM PULM

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.46	Insider Own	9.34%	Shs Outstand	3.43M	Perf Week	-10.30%
Market Cap	7.68M	Forward P/E	-	EPS next Y	-2.23	Insider Trans	0.00%	Shs Float	3.33M	Perf Month	-22.88%
Enterprise Value	-11.30M	PEG	-	EPS next Q	-0.67	Inst Own	16.75%	Short Float	0.37%	Perf Quarter	-21.72%
Income	-8.54M	P/S	-	EPS this Y	-296.55%	Inst Trans	-15.92%	Short Ratio	0.26	Perf Half Y	-33.86%
Sales	0.00M	P/B	0.32	EPS next Y	-30.41%	ROA	-24.99%	Short Interest	0.01M	Perf YTD	-36.67%
Book/sh	6.53	P/C	0.40	EPS next 5Y	-	ROE	-32.58%	52W High	4.18 -50.00%	Perf Year	-39.24%
Cash/sh	5.27	P/FCF	-	EPS past 3/5Y	- -	ROIC	-37.70%	52W Low	2.16 -3.24%	Perf 3Y	-96.19%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- 42.93%	Gross Margin	-	Volatility	4.46% 6.97%	Perf 5Y	-99.82%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-463.97%	Oper. Margin	-	ATR (14)	0.14	Perf 10Y	-99.99%
Dividend Ex-Date	-	Quick Ratio	8.79	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	31.11	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	8.79	EPS Q/Q	100.77%	SMA20	-11.82%	Beta	-0.75	Target Price	12.00
Payout	0.00%	Debt/Eq	0.02	Sales Q/Q	-	SMA50	-18.23%	Rel Volume	3.41	Prev Close	2.16
Employees	12	LT Debt/Eq	0.01	Earnings	Nov 07 BMO	SMA200	-28.45%	Avg Volume	46.73K	Price	2.09
IPO	Feb 13, 2015	Option/Short	No / Yes	EPS/Sales Surpr.	101.36% -100.00%	Trades		Volume	159,359	Change	-3.24%

Nov-07-25 06:00AM	Kiora Pharmaceuticals Reports Third Quarter 2025 Results; Company Advances Pipeline with Two Actively Enrolling Phase 2 Clinical Trials for Retinal Diseases (Newsfile)
Oct-30-25 09:00AM	Kiora Pharmaceuticals Joins RARE-X Vision Consortium Promoting Collaboration and Development of New Treatments for Rare Ocular Disorders (PR Newswire)
Oct-15-25 07:00AM	Kiora Pharmaceuticals to Participate in the 2025 Maxim Growth Summit and Eyecelerator @ AAO 2025 (Newsfile)
Sep-04-25 07:00AM	Kiora Pharmaceuticals to Webcast On-Demand Presentation at The H.C. Wainwright 27th Annual Global Investment Conference (Newsfile)
Aug-08-25 07:00AM	Kiora Pharmaceuticals Reports Second Quarter 2025 Results; Company Advances Pipeline with Two Active Phase 2 Clinical Trials for Retinal Diseases (Newsfile)
07:00AM	Loading…
Aug-07-25 07:00AM	Kiora Pharmaceuticals to Showcase Its Retinal Disease Therapeutic Pipeline at The H.C. Wainwright 5th Annual Ophthalmology Virtual Conference (Newsfile)
Aug-01-25 11:51AM	Vicarious Surgical names Stephen From as next CEO (MedTech Dive)
Jul-31-25 04:30PM	Vicarious Surgical Announces Leadership Transition: Stephen From, Healthcare Industry Veteran, Appointed Chief Executive Officer (Business Wire)
Jul-22-25 08:55AM	Kiora Pharmaceuticals Granted U.S. Patent Expanding Protection for KIO-104 in the Treatment of Ocular Disease (Newsfile)
Jul-16-25 12:00PM	Kiora Pharmaceuticals (KPRX) Upgraded to Strong Buy: Here's What You Should Know (Zacks) +5.00%
Jun-03-25 07:00AM	Kiora Pharmaceuticals and Senju Pharmaceutical Partner on KIO-301 for the Treatment of Retinal Diseases in Asia (Newsfile) +36.84%
May-09-25 07:00AM	Kiora Pharmaceuticals Reports First Quarter Results; Initiating Two Phase 2 Trials for Treatment of Retinal Diseases; Cash and Short-term Investments Expected to Fund Operations into Late 2027 (Newsfile)
May-05-25 07:00AM	Kiora Pharmaceuticals Presents In Vivo Preclinical Data at ARVO 2025 Demonstrating the Potential of KIO-104 to Treat Proliferative Vitreoretinopathy (Newsfile)
Apr-04-25 07:00AM	Kiora Pharmaceuticals to Present at The 24th Annual Needham Virtual Healthcare Conference (Newsfile) -7.31%
Mar-25-25 07:00AM	Kiora Pharmaceuticals Reports 2024 Results; Retinal Disease Drug Development Pipeline Continues to Advance; Cash and Short-Term Investments Expected to Fund Operations into 2027 (Newsfile) -5.00%
07:00AM	Loading…
Mar-12-25 07:00AM	Kiora Pharmaceuticals to Present Preclinical Data on KIO-104 for the Treatment of Proliferative Vitreoretinopathy at the ARVO 2025 Annual Meeting (Newsfile)
Feb-13-25 07:00AM	Kiora Pharmaceuticals Secures U.S. Composition-of-Matter Patent Expanding Protection of Its Anti-Inflammatory Compound KIO-104 (Newsfile)
Feb-11-25 06:45AM	Kiora Receives Approval to Initiate KLARITY, a Phase 2 Clinical Trial of KIO-104 for the Treatment of Retinal Macular Edema (Newsfile) -9.44%
Nov-08-24 07:00AM	Kiora Pharmaceuticals Reports Third Quarter Results; Retinal Disease Pipeline Advancing Two Phase 2 Studies (Newsfile)
Oct-30-24 07:28AM	Kiora Pharmaceuticals Gains Approval for Phase 2 Trial (TipRanks)
Oct-29-24 06:45AM	Kiora Pharmaceuticals Receives Investigational New Drug Approval to Initiate ABACUS-2, a Phase 2 Clinical Trial of KIO-301 for the Treatment of Retinitis Pigmentosa (Newsfile)
Sep-25-24 09:55AM	Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences (Newsfile)
Aug-09-24 02:53PM	KPRX Stock Earnings: Kiora Pharmaceuticals Beats EPS for Q2 2024 (InvestorPlace)
07:00AM	Kiora Pharmaceuticals Reports Second Quarter Results; Retinal Disease Drug Development Pipeline Advancing Toward Two Phase 2 Studies (Newsfile)
Aug-06-24 07:03AM	Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences (Newsfile)
Jul-30-24 06:45AM	Kiora Pharmaceuticals Receives European Orphan Medicinal Product Designation for KIO-301 for the Treatment of Inherited Retinal Dystrophies (Newsfile)
Jul-10-24 07:00AM	Kiora Pharmaceuticals to Participate in Jones Healthcare Seaside Summit 2024; Kiora Invites Investors to Submit Questions Following the Conference Presentation (Newsfile)
Jul-01-24 06:54AM	Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors (Newsfile)
Jun-25-24 06:45AM	Vitreoretinal Surgeon and Key Thought Leader Roger Goldberg, M.D., Joins Kiora Pharmaceuticals' Scientific Advisory Board (Newsfile)
Jun-18-24 09:40AM	Is Kiora Pharmaceuticals (KPRX) Stock Undervalued Right Now? (Zacks)
06:44PM	Loading…
May-29-24 06:44PM	Lytham Partners Spring 2024 Investor Conference Starts Tomorrow, May 30, 2024 (Newsfile) -6.36%
May-20-24 07:00AM	Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences (Newsfile)
May-10-24 01:54PM	KPRX Stock Earnings: Kiora Pharmaceuticals Beats EPS for Q1 2024 (InvestorPlace)
07:00AM	Kiora Pharmaceuticals Reports First Quarter Results; Update on Pipeline of Drugs Targeting Retinal Disease (Newsfile)
May-08-24 07:00AM	Kiora Pharmaceuticals to Present at The Citizens JMP Life Sciences Conference (Newsfile)
May-06-24 07:00AM	Kiora Pharmaceuticals Reports Additional Clinical Data for KIO-301 Showing a Statistically Significant Increase in Brain Activity in the Visual Cortex in Patients with Retinitis Pigmentosa (Newsfile)
Apr-11-24 07:00AM	Kiora Pharmaceuticals Receives Grant from Choroideremia Research Foundation to Fund Novel Clinical Trial Endpoints for Inherited Retinal Diseases; Approval Granted to Initiate Clinical Validation Study (Newsfile)
Apr-05-24 07:00AM	Kiora Pharmaceuticals to Present at Upcoming Investor Conferences (Newsfile)
Mar-28-24 06:45AM	Kiora Pharmaceuticals to Present Additional Data from Its ABACUS-1 Trial in Retinitis Pigmentosa at the ARVO 2024 Annual Meeting (Newsfile) +14.41%
Mar-25-24 07:00AM	Kiora Pharmaceuticals Reports 2023 Results; Continues to Advance Pipeline of Treatments for Rare Retinal Diseases (Newsfile)
Mar-08-24 07:00AM	Kiora Announces Publication of Phase 1 Study Demonstrating Safety, Tolerability and Anti-Inflammatory Activity of KIO-101 in the Treatment of Inflammation of the Eye (Newsfile)
Feb-01-24 08:14AM	Why Is Kiora Pharmaceuticals (KPRX) Stock Up 39% Today? (InvestorPlace) +53.87%
Jan-31-24 06:40PM	Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million (Newsfile) -6.20%
05:15PM	Kiora Pharmaceuticals and Th a Open Innovation Enter Strategic Agreement to Develop and Commercialize KIO-301 for the Treatment of Inherited Retinal Diseases; Total Deal Value of up to $301 Million includes $16 Million Upfront, up to $285 Million in Clinical Development, Regulatory and Commercial Milestones, Plus Commercial Royalties (Newsfile)
Nov-17-23 01:54PM	Breaking ground in vision restoration: Kiora Pharmaceuticals reveals promising results with KIO-301 (News Direct)
Nov-09-23 07:18AM	Kiora Pharmaceuticals Reports Q3 2023 Results; Expanding Clinical Development of KIO-301 for Inherited Retinal Diseases Based on Encouraging Results of ABACUS-1 Study in Retinitis Pigmentosa (Newsfile)
Nov-04-23 12:15PM	AAO Late-Breaking: Kiora's Small Molecule Photoswitch Demonstrates Meaningful Vision Improvements in Blind Patients with Retinitis Pigmentosa (Newsfile)
Oct-16-23 07:00AM	Kiora Pharmaceuticals to Participate in the Lytham Partners Fall 2023 Investor Conference (Newsfile) -5.30%
Oct-03-23 07:00AM	Kiora Pharmaceuticals Receives Investigational New Drug Application Approval to Expand Phase 1b Study of KIO-301 in Inherited Retinal Diseases; To Enroll Patients with Choroideremia and Additional Patients with Late-Stage Retinitis Pigmentosa (Newsfile)
Sep-21-23 07:00AM	Kiora Pharmaceuticals Appoints Praveen Tyle, PhD, as New Chairman; Succeeds Paul Chaney Who is Retiring After Serving 17 Years (Newsfile)
Sep-18-23 07:00AM	Kiora Pharmaceuticals Completes Last Patient, Last Visit in Phase 1B Trial of KIO-301 in Patients with Retinitis Pigmentosa (Newsfile)
Sep-14-23 07:01AM	Kiora Pharmaceuticals to Present Topline Results from the ABACUS Study at American Academy Ophthalmology (AAO); Phase 1b Study Evaluating KIO-301 in Retinitis Pigmentosa (Newsfile)
Sep-01-23 07:00AM	Kiora Pharmaceuticals Adjourns Special Meeting of Stockholders to September 27 (Newsfile)
Aug-29-23 01:43PM	Kiora Pharmaceuticals and the Choroideremia Research Foundation to Host Webinar on the Development of Molecular Photoswitches for Inherited Retinal Diseases (Newsfile)
Aug-23-23 07:33PM	Is Kiora Pharmaceuticals Significantly Undervalued? A Comprehensive Valuation Analysis (GuruFocus.com) +22.55% -16.80%
07:00AM	Kiora Pharmaceuticals Granted U.S. and European Patents for Local Ocular Delivery of the KIO-100 Family of Compounds; New IP Specifically Includes Treatment of Posterior Non-Infectious Uveitis (Newsfile)
Aug-22-23 01:06PM	Kiora Pharmaceuticals Taps B2i Digital to Deploy Data-Driven Investor Awareness Program (Newsfile)
Aug-16-23 07:00AM	Kiora Pharmaceuticals Webcasts Its Investor Presentation from the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference (Newsfile)
Aug-08-23 07:00AM	Kiora Pharmaceuticals Announces Q2 2023 Earnings and Business Update, Highlighting Pipeline Updates and Clinical Development Progress (Newsfile)
Aug-03-23 07:00AM	Kiora Pharmaceuticals, Inc. and Choroideremia Research Foundation Partner to Advance Novel Choroideremia Treatment (Newsfile)
Aug-01-23 07:00AM	Biotech Leader Carmine Stengone Joins Kiora Pharmaceuticals' Board of Directors (Newsfile)
Jul-05-23 07:00AM	Kiora Pharmaceuticals Receives $1.2 Million in Research Tax Credits to Advance the Treatment of Ophthalmic Disease (Newsfile)
Jun-23-23 08:35AM	Life Science Investor Forum: Presentations Now Available for Online Viewing (GlobeNewswire) -6.57%
Jun-20-23 10:58AM	Life Science Investor Forum Agenda Announced for June 22nd (GlobeNewswire) -7.68%
Jun-15-23 07:00AM	Kiora Pharmaceuticals and Sentrx Animal Care Amend Existing Manufacturing Licensing Agreement for KIO-201 (Newsfile) +5.49%
Jun-14-23 08:00AM	Kiora Pharmaceuticals to Present at Upcoming Investor Conferences (Newsfile)
Jun-06-23 04:30PM	Kiora Pharmaceuticals Announces Closing of $6.3 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option (Newsfile) -7.53%
Jun-02-23 08:30AM	Kiora Pharmaceuticals Announces Pricing of $5.5 Million Underwritten Public Offering (Newsfile) -49.55%
May-09-23 07:00AM	Kiora Pharmaceuticals Reports First Quarter Results; Positive Clinical Data Driving Significant Progress Advancing Pipeline of Eye Disease Treatments (Newsfile)
May-01-23 07:00AM	Kiora Pharmaceuticals Presents Encore Imaging Results of KIO-301 for Retinitis Pigmentosa at ASNR 2023 Meeting (Newsfile) -10.36%
Apr-27-23 02:55PM	Kiora's Investigational Treatment for Retinitis Pigmentosa, KIO-301, Demonstrates Visual Function Restoration in Patients Who Are Blind (Newsfile) +8.90%
Apr-26-23 07:00AM	Kiora Pharmaceuticals' KIO-201 Heals Wounds in Phase 2 Trial of Patients with Persistent Corneal Epithelial Defects (Newsfile) +6.98%
Apr-21-23 07:00AM	Inherited Retinal Disease Expert, Mark Pennesi, M.D., Ph.D., Joins Kiora Pharmaceuticals' Scientific Advisory Board (Newsfile) +14.49%
Apr-17-23 07:00AM	Kiora Pharmaceuticals Initiates Phase 2 Trial of KIO-101 for the Treatment of Ocular Presentation of Autoimmune Diseases (Newsfile)
Mar-30-23 07:00AM	Kiora Announces the Acceptance of Late-Breaking Abstract on Phase 1b Study of KIO-301 in Retinitis Pigmentosa at The American Society of Neuroradiology 2023 Meeting (Newsfile)
Mar-23-23 07:00AM	Kiora Pharmaceuticals Reports 2022 Financial Results; Provides Update on Clinical Development Progress (Newsfile) -9.37%
Mar-10-23 07:00AM	Kiora Pharmaceuticals Announces the Acceptance of Three Abstracts at the 2023 ARVO Annual Meeting (Newsfile)
Feb-09-23 12:00PM	Biotech Stock Roundup: AMGN, GILD, BMY, REGN's Q4 Results, KPRX Up on Study Update (Zacks)
Feb-07-23 08:00AM	Kioras stock rallies as eye drop treatment moves into mid-stage clinical trial (MarketWatch) +38.72%
07:00AM	Kiora Pharmaceuticals Receives Investigational New Drug Approval for Phase 2 Study of KIO-101 for Treatment of Ocular Presentation of Autoimmune Diseases (Newsfile)
Feb-03-23 07:00AM	Kiora Pharmaceuticals Enters into Two Equity Purchase Agreements with Lincoln Park Capital (Newsfile)
Jan-09-23 07:00AM	Kiora Pharmaceuticals Highlights Anticipated Clinical and Corporate Milestones for 2023; Webcast Now Available on Company Website (Newsfile)
Jan-03-23 07:01AM	Kiora Pharmaceuticals Completes Enrollment of Clinical Trial Evaluating KIO-201 for Persistent Corneal Epithelial Defects; Results Expected to be Reported in 1H 2023 (Newsfile)
Dec-14-22 08:19AM	Stonegate Healthcare Reviews Retinitis Pigmentosa (Newsfile)
Nov-18-22 08:30AM	Kiora Pharmaceuticals Enters Into Agreements to Raise $3.12 Million From the Exercise of Previously Issued Class A Warrants (Newsfile) -35.85%
Nov-17-22 06:45AM	Kiora Pharmaceuticals Doses First Patient in ABACUS Phase 1b Study Evaluating KIO-301 for Retinitis Pigmentosa (Newsfile)
Nov-09-22 06:45AM	Kiora Pharmaceuticals Provides 3rd Quarter 2022 Business and Financial Update; Dosing of KIO-301 in Phase 1 Trial for Retinitis Pigmentosa to Begin Before Year's End (Newsfile) -5.76%
Oct-31-22 08:01AM	KOL Webinar on Genetic Blindness Points to Promise of Kioras Pioneering Solution--Clinical Data in Q1 (News Direct)
Oct-17-22 08:00AM	Kiora Pharmaceuticals Announces Publication of Phase 1 Trial Results for KIO-100 as a Treatment for Ocular Inflammatory Disease (Newsfile)
Oct-13-22 06:45AM	Kiora Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements (Newsfile)
Sep-28-22 11:44AM	Battling Blindness: Virtual Investor Event on Treatments for Retinitis Pigmentosa to Be Held October 19; Panelists include Kiora Pharmaceuticals, Foundation Fighting Blindness, and Retinal Surgeon Christine Kay, M.D. (Newsfile) +6.06%
Sep-26-22 06:45AM	Kiora Pharmaceuticals to Implement 1-for-40 Reverse Split (Newsfile) -10.05%
Sep-13-22 06:45AM	Kiora Pharmaceuticals Appoints Melissa Tosca as Executive Vice President of Finance (Newsfile) +21.00%
Aug-15-22 06:30AM	KPRX: What a difference a year makes! (Zacks Small Cap Research)
Aug-12-22 06:45AM	Kiora Pharmaceuticals Reports First Half 2022 Business Update and Financial Results (Newsfile) -10.71%
Jul-28-22 06:45AM	Kiora Pharmaceuticals Issued US Patent Covering KIO-201 Technology in Combination with Antibiotics (Newsfile)
Jul-26-22 04:38PM	Kiora Pharmaceuticals Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option (Newsfile)
Jul-22-22 08:30AM	Kiora Pharmaceuticals Announces Pricing of $5.2 Million Underwritten Public Offering (Newsfile) -39.76%
Jul-05-22 06:45AM	Kiora Pharmaceuticals Announces First Patient Enrolled in Phase 2 Study Evaluating KIO-201 for Persistent Corneal Epithelial Defects (Newsfile)
Jun-27-22 06:53AM	Kiora Pharmaceuticals Receives Clinical Trial Approval for First-in-Human Evaluation of KIO-301 to Restore Vision in Patients with Retinitis Pigmentosa (Newsfile)

Kiora Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes KIO-301, which is designed to restore vision in patients with inherited and age-related degenerative retinal disease, KIO-101 for patients with Ocular Presentation of Rheumatoid Arthritis, KIO-201 for patients undergoing PRK surgery for corneal wound repair after refractive surgery, and KIO-102. The company was founded in 1998 and is headquartered in Encinitas, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

KPRX

Kiora Pharmaceuticals Inc

Upgrade your FINVIZ experience